PTC Therapeutics, Inc. (PTCT) key performance indicators and operating metrics (9 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Net Product Revenue Across the Commercial Portfolio | 225.57M | FY2026-Q1 |
| Collaboration and License Revenue | 143K | FY2026-Q1 |
| Emflaza Net Product Revenue | 21.5M | FY2026-Q1 |
| Research and Development Expense (Non-GAAP) | 89.74M | FY2026-Q1 |
| Selling, General and Administrative Expense (Non-GAAP) | 73.89M | FY2026-Q1 |
| Translarna Net Product Revenue | 59M | FY2026-Q1 |
| Patients on Commercial Therapy Worldwide | 1.24K | FY2026-Q1 |
| Royalty Revenue | 46.84M | FY2026-Q1 |
| Duchenne Muscular Dystrophy Franchise Revenue | 85.9M | FY2025-Q3 |
Back to PTCT overview · PTCT earnings · PTCT holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.